BeiMedPlus | Brasil - Página 8 de 15

memo

Memo inOncology - ASH 2021 congress report

Report on updates in the treatment of B-cell malignancies presented at ASH 2021.

Reading

26 abr 2022

BeiGene

Mode of action of PD-1 inhibitors

A video about the mode of action (MoA) of PD-1 inhibitors.

Vídeos

6 abr 2022

BeiGene

Safety analysis in patients with advanced squamous NSCLC

Poster from ELCC2022 investigating the combination of PD-1 inhibition and chemotherapy as a potential therapeutic option for advanced squamous (sq) non-small cell lung cancer (NSCLC) patients.

Reading

6 abr 2022

BeiGene

Therapeutic option for patients with untreated LS-SCLC

Poster from ELCC2022 investigating the synergistic effects of inhibiting PD-1 and TIGIT in combination with chemoradiotherapy (cCRT) in patients with treatment naïve (TN) limited-stage small cell lung cancer (LS-SCLC).

Reading

6 abr 2022

BeiGene

Mode of action of TIGIT inhibitors

Dual targeting of TIGIT and PD-1 may be effective in overcoming tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors. Watch the video to learn more.

Vídeos

6 abr 2022

Carregar mais

Memo inOncology - ASH 2021 congress report

Mode of action of PD-1 inhibitors

Safety analysis in patients with advanced squamous NSCLC

Therapeutic option for patients with untreated LS-SCLC

Mode of action of TIGIT inhibitors

Está a sair do website beigenemedical-info-develop.go-vip.net

Está a sair do website beigenemedical-info-develop.go-vip.net

Welcome to BeiMedPlus

Memo inOncology - ASH 2021 congress report

Mode of action of PD-1 inhibitors

Safety analysis in patients with advanced squamous NSCLC

Therapeutic option for patients with untreated LS-SCLC

Mode of action of TIGIT inhibitors

Está a sair do website beigenemedical-info-develop.go-vip.net

Está a sair do website beigenemedical-info-develop.go-vip.net